These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 34247265)
21. Further studies of the role of opioid receptors in the nigra in the morphine withdrawal syndrome. Baumeister AA; Richard AL; Richmond-Landeche L; Hurry MJ; Waguespack AM Neuropharmacology; 1992 Sep; 31(9):835-41. PubMed ID: 1359441 [TBL] [Abstract][Full Text] [Related]
22. Anxiolytic-like effects of morphine and buprenorphine in the rat model of fear-potentiated startle: tolerance, cross-tolerance, and blockade by naloxone. Glover EM; Davis M Psychopharmacology (Berl); 2008 Jun; 198(2):167-80. PubMed ID: 18324390 [TBL] [Abstract][Full Text] [Related]
23. An-jun-ning, a traditional herbal formula, attenuates spontaneous withdrawal symptoms via modulation of the dopamine system in morphine-dependent rats. Gao JL; Tu SA; Liu J; Zhang JM; Huang Y; Han M; Liang JH BMC Complement Altern Med; 2014 Aug; 14():308. PubMed ID: 25134609 [TBL] [Abstract][Full Text] [Related]
24. GABA and opioid mechanisms of the central amygdala underlie the withdrawal-potentiated startle from acute morphine. Cabral A; Ruggiero RN; Nobre MJ; Brandão ML; Castilho VM Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):334-44. PubMed ID: 19150477 [TBL] [Abstract][Full Text] [Related]
25. The effects of buprenorphine on fentanyl withdrawal in rats. Bruijnzeel AW; Marcinkiewcz C; Isaac S; Booth MM; Dennis DM; Gold MS Psychopharmacology (Berl); 2007 May; 191(4):931-41. PubMed ID: 17211652 [TBL] [Abstract][Full Text] [Related]
26. Focal kappa-opioid receptor-mediated dependence and withdrawal in the nucleus paragigantocellularis. Sinchaisuk S; Ho IK; Rockhold RW Pharmacol Biochem Behav; 2002 Dec; 74(1):241-52. PubMed ID: 12376173 [TBL] [Abstract][Full Text] [Related]
28. Differential tolerance to antinociceptive effects of mu opioids during repeated treatment with etonitazene, morphine, or buprenorphine in rats. Walker EA; Young AM Psychopharmacology (Berl); 2001 Mar; 154(2):131-42. PubMed ID: 11314675 [TBL] [Abstract][Full Text] [Related]
29. Disulfiram attenuates morphine or methadone withdrawal syndrome in mice. de Cordé A; Krząścik P; Wolińska R; Kleczkowska P; Filip M; Bujalska-Zadrożny M Behav Pharmacol; 2018 Aug; 29(5):393-399. PubMed ID: 29462108 [TBL] [Abstract][Full Text] [Related]
30. Effects of buprenorphine on motility in morphine post-dependent rats. Bartoletti M; Gaiardi M; Gubellini C Pharmacol Res; 1999 Oct; 40(4):327-32. PubMed ID: 10527644 [TBL] [Abstract][Full Text] [Related]
31. Neuropeptide trefoil factor 3 attenuates naloxone-precipitated withdrawal in morphine-dependent mice. Wu P; Shi HS; Luo YX; Zhang RX; Li JL; Shi J; Lu L; Zhu WL Psychopharmacology (Berl); 2014 Dec; 231(24):4659-68. PubMed ID: 24825609 [TBL] [Abstract][Full Text] [Related]
32. Quantitative evaluation of opioid withdrawal signs in rats repeatedly treated with morphine and injected with naloxone, in the absence or presence of the antiabstinence agent clonidine. Pinelli A; Trivulzio S J Pharmacol Toxicol Methods; 1997 Nov; 38(3):117-31. PubMed ID: 9523765 [TBL] [Abstract][Full Text] [Related]
33. Ultrasounds during morphine withdrawal in rats. Vivian JA; Miczek KA Psychopharmacology (Berl); 1991; 104(2):187-93. PubMed ID: 1876663 [TBL] [Abstract][Full Text] [Related]
34. In vivo and in vitro attenuation of naloxone-precipitated experimental opioid withdrawal syndrome by insulin and selective KATP channel modulator. Singh P; Sharma B; Gupta S; Sharma BM Psychopharmacology (Berl); 2015 Jan; 232(2):465-75. PubMed ID: 25059539 [TBL] [Abstract][Full Text] [Related]
35. Voluntary Running-Wheel Activity, Arterial Blood Gases, and Thermal Antinociception in Rats after 3 Buprenorphine Formulations. Johnson RA J Am Assoc Lab Anim Sci; 2016; 55(3):306-11. PubMed ID: 27177564 [TBL] [Abstract][Full Text] [Related]
36. In Utero Exposure to Norbuprenorphine, a Major Metabolite of Buprenorphine, Induces Fetal Opioid Dependence and Leads to Neonatal Opioid Withdrawal Syndrome. Griffin BA; Caperton CO; Russell LN; Cabanlong CV; Wilson CD; Urquhart KR; Martins BS; Zita MD; Patton AL; Alund AW; Owens SM; Fantegrossi WE; Moran JH; Brents LK J Pharmacol Exp Ther; 2019 Jul; 370(1):9-17. PubMed ID: 31028107 [TBL] [Abstract][Full Text] [Related]
37. Chronic naloxone-induced supersensitivity affects neither tolerance to nor physical dependence on morphine at hypothalamus-pituitary-adrenocortical axis. Alcaraz C; Vargas ML; Milanés MV Neuropeptides; 1996 Feb; 30(1):29-36. PubMed ID: 8868296 [TBL] [Abstract][Full Text] [Related]